Table 4.

Statistical analyses of the hyperlocomotor effects of oxycodone, morphine, and cocaine in all lines (Fig. 3)

Item	Figure	Experiment	Statistical test	Effect or Interaction	Main effect	flMOR	D1flMOR	D2flMOR	A2aflMOR	ChATflMOR
a	3A	Oxycodone dose response: dose response (0 mg/kg or saline)	One-way ANOVA	Genotype	F(4,36) = 2.54, p = 0.056	Reference genotype n = 8	N.S. n = 8	N.S. n = 8	N.S. n = 8	N.S. n = 9
b	3A	Oxycodone dose response: dose effect	Two-way ANOVA	Genotype × dose	F(12,145) = 3.76, p < 0.001	3 mg; p = 0.007 vs 0, 10 mg; p = 0.0002 vs 0 n = 8–12	N.S. n = 8–11	3 mg; p = 0.56 vs 0, 10 mg; p < 0.0001 vs 0, n = 8	3 mg; p < 0.0001 vs 0, 10 mg; p < 0.0001 vs 0, n = 6–9	3 mg; p = 0.80 vs 0, 10 mg; p = 0.0013 vs 0 n = 5–9
c	3A	Oxycodone dose response: genotype effect	Two-way ANOVA	Genotype × dose	F(12,145) = 3.76, p < 0.001	Reference genotype	10 mg: p = 0.04	N.S.	3 mg; p = 0.0001, 10 mg; p < 0.0001	N.S.
d	3B	Morphine dose response: dose effect	Two-way ANOVA	Genotype × dose	F(12,148) = 5.7, p < 0.001	10 mg; N.S. 15 mg; p = 0.003 vs 0 n = 8–11	N.S. n = 8–11	10 mg; N.S. 15 mg; p < 0.0001 n = 8–11	10 mg; p < 0.0001, 15 mg; p < 0.0001 n = 5–9	N.S. n = 6–9
e	3B	Morphine dose response: genotype effect	Two-way ANOVA	Genotype × dose	F(12,148) = 5.7, p < 0.001	Reference genotype	15 mg: p = 0.004	N.S.	10 mg; p = 0.0001, 15 mg; p = 0.004	N.S.
f	3C	Cocaine; dose effect	Two-way ANOVA	Treatment × genotype	F(4,83) = 3.77, p = 0.0073	p < 0.0001 Cocaine, n = 21; saline n = 9	p = 0.0018 Cocaine, n = 9; saline n = 14	p = 0.0010 Cocaine, n = 9; saline n = 7	p = 0.0005 Cocaine, n = 9; saline n = 9	p < 0.0001 Cocaine, n = 10; saline n = 7
g	3C	Cocaine; genotype effect	Two-way ANOVA	Treatment × genotype	F(4,83) = 3.77, p = 0.0073	Reference genotype	N.S. for saline and cocaine	N.S. for saline and cocaine	N.S. for saline and cocaine	Saline; N.S. Cocaine; p < 0.0005
h	3D	Locomotor sensitization; flMORs	Two-way ANOVA	Genotype × day	F(2,27) = 3.9, p = 0.049	Oxycodone; p = 0.002 morphine; p = 0.018 n = 11 for both, saline n = 8
i	3E	Locomotor sensitization; D1flMORs	Two-way ANOVA	Genotype × day	F(2,25) = 0.6, p = 0.56		N.S. oxycodone n = 8, morphine n = 11, saline n = 8
j	3F	Locomotor sensitization; D2flMORs	Two-way ANOVA	Genotype × day	F(2,23) = 12.24, p = 0.0002			Oxycodone; p < 0.0001, n = 7, morphine; p < 0.0001 n = 11, saline n = 8
k	3G	Locomotor sensitization; A2aflMORs	Two-way ANOVA	Genotype × day	F(2,25) = 8.23, p = 0.0018				Oxycodone; p < 0.0001 n = 11, morphine; p = 0.15, n = 9, saline n = 8
l	3H	Locomotor sensitization; ChATflMORs	Two-way ANOVA	Genotype × day	F(2,23) = 11.53, p = 0.0003					Oxycodone; p < 0.0001, n = 8, morphine; N.S., n = 9, saline; n = 9
m	3I	Oxycodone intrasession analysis: Day 1	LMM	Genotype × timebin	χ2 = 11.882, p = 0.018	N.A.	N.S., n = 9	N.S., n = 8	N.S., n = 11	N.S., n = 9
n	3J	Oxycodone intrasession analysis: day 1	LMM	Timebin	χ2 = 31.215, p < 0.0001	N.S., n = 11	p = 0.076, n = 9	p = 0.016, n = 8	p < 0.0001, n = 11	N.S., n = 9
o	3K	Oxycodone intrasession analysis: day 3	LMM	Genotype × timebin	N.S.	N.A.	N.S., n = 9	N.S., n = 8	N.S., n = 11	N.S., n = 9
p	3K	Oxycodone intrasession analysis: day 3	LMM	Timebin	χ2 = 12.66, p = 0.027	N.S., n = 11	p < 0.001, n = 9	N.S., n = 8	N.S., n = 11	N.S., n = 9
q	3L	Morphine intrasession analysis: day 1	LMM	Genotype × timebin	χ2 = 21.239, p < 0.001	N.A.	p = 0.002	N.S.	N.S.	N.S.
r	3L	Morphine intrasession analysis: day 1	LMM	Timebin	χ2 = 54.796, p < 0.0001	p < 0.0001	N.S., p = 0.79	p < 0.0001	p < 0.0001	p = 0.002
s	3M	Morphine intrasession analysis: day 3	LMM	Genotype × timebin	χ2 = 32.962, p < 0.0001	N.A.	p < 0.0001	N.S.	N.S.	p < 0.0001
t	3M	Morphine intrasession analysis: day 3	LMM	Timebin	χ2 = 64.194, p < 0.0001	p < 0.0001	N.S., p = 0.56	p < 0.0001	p < 0.0001	p = 0.03

N.S.: not significant, N.A: not applicable.